MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 20, Issue 16, 2014, Pages 4723-4729

  Ji, Xiang Fen ^a   Fan, Yu Chen ^a,b   Gao, Shuai ^a   Yang, Yang ^a   Zhang, Jian Jun ^a   Wang, Kai ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Methylation; MT1G; MT1M; Serum biomarker

Indexed keywords

BIOLOGICAL MARKER; METALLOPROTEIN; METALLOTHIONEIN; MT1G PROTEIN, HUMAN; MT1M PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DNA EXTRACTION; DNA METHYLATION; FEMALE; GENE EXPRESSION; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MORBIDITY; MT1G GANE; MT1M GENE; PATHOLOGY; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TUMOR INVASION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; AREA UNDER THE CURVE; BLOOD; GENETIC SCREENING; GENETICS; LIVER TUMOR; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROMOTER REGION;

AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; FEMALE; GENETIC TESTING; HUMANS; LIVER NEOPLASMS; MALE; METALLOTHIONEIN; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84899639635     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i16.4723     Document Type: Article

References (38)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/ S0140-6736(11)61347-0]
2. Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 2004; 5: 118-125 [PMID: 15244512]
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750 [PMID: 10072408 DOI: 10.1056/NEJM199903113401001]
4. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-1143 [PMID: 9343506 DOI: 10.1016/S0140-6736(05)63789-0]
5. Mohamed NA, Swify EM, Amin NF, Soliman MM, Tag- Eldin LM, Elsherbiny NM. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? Arab J Gastroenterol 2012; 13: 111-115 [PMID: 23122451 DOI: 10.1016/ j.ajg.2012.06.009]
6. De Masi S, Tosti ME, Mele A. Screening for hepatocellular carcinoma. Dig Liver Dis 2005; 37: 260-268 [PMID: 15788210 DOI: 10.1016/j.dld.2004.11.005]
7. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101: 524-532 [PMID: 16542289 DOI: 10.1111/ j.1572-0241.2006.00443.x]
8. Rivenbark AG, Coleman WB. The use of epigenetic biomarkers for preclinical detection of hepatocellular carcinoma: potential for noninvasive screening of high-risk populations. Clin Cancer Res 2007; 13: 2309-2312 [PMID: 17438087 DOI: 10.1158/1078-0432.CCR-07-0086]
9. Zhu J. DNA methylation and hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006; 13: 265-273 [PMID: 16858536 DOI: 10.1007/s00534-005-1054-4]
10. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000; 6: 3516-3521 [PMID: 10999738]
11. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999; 59: 71-73 [PMID: 9892188]
12. Yeo W, Wong N, Wong WL, Lai PB, Zhong S, Johnson PJ. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int 2005; 25: 266-272 [PMID: 15780049 DOI: 10.1111/j.1478-3231.2005.01084.x]
13. Wang J, Qin Y, Li B, Sun Z, Yang B. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem 2006; 39: 344-348 [PMID: 16527261 DOI: 10.1016/j.clinbiochem.2006.01.008]
14. Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI, Wang LY, Chen SY, Chen CJ, Santella RM. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007; 13: 2378-2384 [PMID: 17438096 DOI: 10.1158/1078-0432.CCR-06-1900]
15. West AK, Stallings R, Hildebrand CE, Chiu R, Karin M, Richards RI. Human metallothionein genes: structure of the functional locus at 16q13. Genomics 1990; 8: 513-518 [PMID: 2286373 DOI: 10.1016/0888-7543(90)90038-V]
16. Stennard FA, Holloway AF, Hamilton J, West AK. Characterisation of six aDitional human metallothionein genes. Biochim Biophys Acta 1994; 1218: 357-365 [PMID: 8049263 DOI: 10.1016/0167-4781(94)90189-9]
17. Miles AT, Hawksworth GM, Beattie JH, Rodilla V. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol 2000; 35: 35-70 [PMID: 10755665 DOI: 10.1080/10409230091169168]
18. Cai L, Satoh M, Tohyama C, Cherian MG. Metallothionein in radiation exposure: its induction and protective role. Toxicology 1999; 132: 85-98 [PMID: 10433372 DOI: 10.1016/S0300- 483X(98)00150-4]
19. Babula P, Masarik M, Adam V, Eckschlager T, Stiborova M, Trnkova L, Skutkova H, Provaznik I, Hubalek J, Kizek R. Mammalian metallothioneins: properties and functions. Metallomics 2012; 4: 739-750 [PMID: 22791193 DOI: 10.1039/ c2mt20081c]
20. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 2009; 44: 29-64 [PMID: 19348910 DOI: 10.1016/j.proghi.2008.10.001]
21. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP. Metallothionein expression in human neoplasia. Histopathology 2004; 45: 103-118 [PMID: 15279628 DOI: 10.1111/ j.1365-2559.2004.01922.x]
22. Jacob ST, Majumder S, Ghoshal K. Suppression of metallothionein- I/II expression and its probable molecular mechanisms. Environ Health Perspect 2002; 110 Suppl 5: 827-830 [PMID: 12426140 DOI: 10.1289/ehp.02110s5827]
23. Cai L, Wang GJ, Xu ZL, Deng DX, Chakrabarti S, Cherian MG. Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China. Anticancer Res 1998; 18: 4667-4672 [PMID: 9891538]
24. Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, Cha HC, MacDougald OA, Jacob ST, Ghoshal K. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007; 67: 2736-2746 [PMID: 17363595 DOI: 10.1158/0008-5472. CAN-06-4433]
25. Huang GW, Yang LY. Metallothionein expression in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 650-653 [PMID: 12174372]
26. Tao X, Zheng JM, Xu AM, Chen XF, Zhang SH. Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol Res 2007; 37: 820-827 [PMID: 17517078 DOI: 10.1111/j.1872- 034X.2007.00113.x]
27. Mao J, Yu H, Wang C, Sun L, Jiang W, Zhang P, Xiao Q, Han D, Saiyin H, Zhu J, Chen T, Roberts LR, Huang H, Yu L. Metallothionein MT1M is a tumor suppressor of human hepatocellular carcinomas. Carcinogenesis 2012; 33: 2568-2577 [PMID: 22971577 DOI: 10.1093/carcin/bgs287]
28. Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol 2009; 35: 477-483 [PMID: 19639168]
29. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
30. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/ hep.23190]
31. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
32. Garrett SH, Sens MA, Shukla D, Flores L, Somji S, ToD JH, Sens DA. Metallothionein isoform 1 and 2 gene expression in the human prostate: downregulation of MT-1X in advanced prostate cancer. Prostate 2000; 43: 125-135 [PMID: 10754528]
33. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. Gene expression profiles in normal and cancer cells. Science 1997; 276: 1268-1272 [PMID: 9157888 DOI: 10.1126/science.276.5316.1268]
34. Baba HA, Grabellus F, August C, Plenz G, Takeda A, Tjan TD, Schmid C, Deng MC. Reversal of metallothionein expression is different throughout the human myocardium after prolonged left-ventricular mechanical support. J Heart Lung Transplant 2000; 19: 668-674 [PMID: 10930816 DOI: 10.1016/S1053-2498(00)00074-7]
35. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003; 533: 201-209 [PMID: 14643421 DOI: 10.1016/ j.mrfmmm.2003.07.013]
36. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9: 416-423 [PMID: 12640447 DOI: 10.1038/nm843]
37. Chung JH, Lee HJ, Kim BH, Cho NY, Kang GH. DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch 2011; 459: 201-211 [PMID: 21494759 DOI: 10.1007/s00428-011-1079-9]
38. Henrique R, Jerónimo C, Hoque MO, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1274-1278 [PMID: 15894685 DOI: 10.1158/1055-9965. EPI-04-0659]